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The efficacy of a sumatriptan and 
naproxen combination pill in a patient with 
chronic migraines who discontinued 
triptan therapy in the past due to a self-
reported poor response to sumatriptan 
monotherapy 
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ABSTRACT A clinical decision report using: 
Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. 
Headache. 2009;49(7):971-982. https://doi.org/10.1111/j.1526-4610.2009.01458.x  
for a patient with chronic migraines who had self-reported poor response to sumatriptan monotherapy. 
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Clinical-Social Context 
Ms. Sue Brown [pseudonym] is a 36-year-old African American female that presented to the medicine clinic to 
discuss her persistent migraine symptoms despite prior attempts at pharmacological intervention. Her past 
medical history is significant for hypertension, opioid use disorder, and migraines. Her hypertension has been well 
controlled for three years on lisinopril 20mg and chlorthalidone 50mg. Ms. Brown’s surgical history includes a 
cesarean section six years ago. After the procedure, Ms. Brown was prescribed morphine for pain control, to which 
she subsequently developed dependence. After a year of opioid dependence, she attended rehabilitation and has 
been abstinent. She currently lives in a suburban neighborhood with her two children and boyfriend and feels safe 
at home. She works as a cashier, is enrolled in Medicaid, and is able to support her family’s needs with the addition 
of her boyfriend’s salary. She noted that she has adequate access to healthcare and food, is using the Nexplanon 
implant for contraception, and has family close by that helps her take care of her children when she works. She has 
a 10th grade education and does not smoke tobacco, drink alcohol, or use any drugs. 
Ms. Brown noted that she has had right-sided migraines lasting 8-14 hours for years without a clear trigger. During 
her migraines, she is unable to leave her bed as light and sound worsen her symptoms. Initially, her migraines were 
intermittently controlled on oral sumatriptan 100mg. Although not optimal, Ms. Brown noted that this was the 
most effective solution so far, so she stuck with it to see if it would improve over time. Due to the loss of a family 
member and the stress of the COVID-19 pandemic, her migraines no longer respond to medication and occur 6-8 
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times per month. During this time, Ms. Brown discontinued her use of sumatriptan as it was no longer effective. 
She now misses work and family time due to her symptoms. She wishes to restart sumatriptan with an additional 
medication because she had not had any prior side effects. Additionally, she has a family member with similar 
migraines that was treated with naproxen, so she is interested in seeing if that could help. 
Clinical Question 
Does the addition of naproxen to a triptan significantly reduce severe migraine symptoms for a patient that has already taken and 
discontinued sumatriptan due to decreasing efficacy in treating recurrent migraines? 
Research Article 
Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. 
Headache. 2009;49(7):971-982. https://doi.org/10.1111/j.1526-4610.2009.01458.x 1 
Description of Related Literature 
The literature search was performed using PubMed advanced key word searches. The search began by selecting for clinical trials (CT) 
and randomized control trials (RCT) with the key terms “migraine” and “sumatriptan.” This search revealed 396 manuscripts, so the 
search criteria needed to be narrowed. 
The next search selected for CT and RCT after the year 2005, using the key terms “migraine,” “sumatriptan,” and “naproxen.” This 
yielded 30 results, of which three discussed menstruation-related migraines, three used adolescents as their study group, and four 
discussed the pharmacokinetics of medications, so these could be excluded from further review. In addition, Ms. Brown had been 
taking sumatriptan for a number of years, so 17 of the remaining 20 manuscripts could be excluded because the patients were either 
triptan naïve or prescribed a different abortant migraine medication prior to the study. This left three studies which are reviewed 
below. 
Landy et al., 2007 is a RCT that looked at patients self-reported ability to function, be productive, and satisfied after taking a 
combined pill of sumatriptan 85mg and naproxen 500mg compared to a control. Patients were more satisfied, productive, and 
functional with the combined medication than the other treatment groups.2 The study cohort did not include groups that had poor 
response to triptans, so it cannot be expanded to include Ms. Brown.  
Edwards et al., 2012 is a RCT that assessed patient’s cognitive function before and after treatment for migraine as an indicator of 
migraine severity using either a combination drug of sumatriptan 85mg and naproxen 500mg or a control. The authors found 
improvement in recovery time and cognitive ability after treatment with the combined medication.3 Unlike Ms. Brown, these 
patients were well-controlled on their migraine medications prior to enrollment in the study.  
Mathew et al., 2009 is a RCT that evaluates the efficacy and tolerability of the combined sumatriptan 85mg and naproxen 500mg 
medication against a control in patients with severe migraines that were unable to continue triptan treatment alone due to poor 
response. The authors identified benefit of this medication compared to the placebo in all endpoints, indicating efficacy of the drug 
in this cohort.1 
This manuscript was chosen as the most appropriate to answer our clinical question of the efficacy of sumatriptan/naproxen in a 
cohort with a history of limited efficacy with sumatriptan alone. While it was not the only manuscript to identify the efficacy of the 
sumatriptan/naproxen combined medication, it was the only one to do so in a group that had poor responsiveness to sumatriptans 
in the past.4,5 Thus, it has clinical significance in this cohort. Notably, the significant benefit found in this study with the 
sumatriptan/naproxen combined medication was also seen in other studies that used patients that were triptan-naïve and patients 
that were effectively treated with sumatriptan before the study. This study can be defined as Level A evidence when referencing the 
Strength of Recommendations Taxonomy (SORT) criteria due to its high quality as an RCT with support from other published 
literature.6 
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Critical Appraisal 
The Mathew et al., 2009 manuscript describes two replicate randomized, double-blinded, placebo-controlled, crossover studies.1 
This crossover design allowed the authors to enroll a smaller number of patients while still obtaining the same amount of data as 
each patient participated as both a placebo and treatment. In a self-reported pain-derived study every patient quantifies their level 
of pain in a different way. Using patients as both a control and treatment decreased the between-subject variability. The study 
design allowed for effective randomization because each patient participated in both groups, so the only randomization occurred 
during the first screening visit before any recording of migraines and consisted of which treatment came first.  
It can be argued that these studies meet criteria to be classified as moderate to strong Strength of Recommendation. The studies 
were blinded, had intention-to-treat analysis, and were of adequate follow-up and size with the crossover design in place. This was 
the first study to analyze more than one short-acting triptan at a time in poor responders. Thus, the data is not strongly supported 
with other similar RCTs, decreasing this manuscript’s SORT Level of Evidence to 2.6 
These studies recruited patients between the ages of 18-65 with a poorly controlled migraine history on short-acting triptans that 
discontinued triptans prior to enrollment. The patients themselves were enlisted from 48 different sites around the country, with 
>90% originating from headache or neurology clinics. Thus, there was inherent participation bias as only patients with complaints of 
poorly treated migraines were likely to join the study as they were the ones being seen at these clinics. Because the authors were 
able to recruit >120 patients that successfully documented two migraine attacks, the study had >95% power to detect a 20% 
difference between the placebo and treatment. Thus, there were significant similarities between Ms. Brown and the study 
populations. Additionally, there was an attrition rate of 24% in one study and 22% in the second study. This is a notably high attrition 
rate, especially for a population suffering from frequent migraines that is looking for an effective treatment. As the study mentions, 
a majority of the patients that did not continue in the study were lost to follow-up or did not have enough migraines to be included. 
While the patients that were lost to follow up could have had poor response to the treatment so they stopped following the 
protocol, those that were removed from the study population due to a low number of migraines could have had improvement with 
treatment. Thus it was not necessarily just the naproxen and triptan treatment regimen that caused the high attrition rate, but the 
interest of the patients and severity of their disease. That said, follow-up studies with a broader patient population should be 
conducted to confirm this finding. 
The patients selected for the study were very similar to Ms. Brown, but not perfect. While she did not meet any of the exclusion 
criteria, she was African American. Only 3% of the cohort in study 1 and 7% in study 2 were African American, with >89% in both 
studies reporting as white. While unlikely to change the results of the manuscript, it is notable that she fell in the minority patient 
population studied. In addition, only 9% and 14% of patients in study 1 and study 2 were recorded to have had poor response to 
sumatriptan. Even though she was included into this minority, the results showed an average improvement in every fast-acting 
triptan included into the study groups, so this is unlikely to have an effect on her response. 
To effectively provide data on the efficacy and tolerability in patients that were self-reported non-responders to triptan medication, 
these two studies attempted to report patient-oriented results. The primary endpoint for efficacy of the combined 
sumatriptan/naproxen medication was 2-24 hours of a sustained pain-free response. The second endpoint was the percentage of 
patients without pain 2 hours post dose. Both of these endpoints focus on the patient experience of migraines as their baseline to 
identify the medication’s effectiveness. Both of the efficacy and the tolerability endpoints were reported in the study. The study 
medication was found to be significantly more effective than placebo for abortion of migraine pain for a 2-24 hour sustained pain-
free response as well as 2 hours post dose. The percentage of patients with at least one adverse event due to drug-related effects 
was 8% and 7% in the two studies for the study medication. Of these adverse events, only one was deemed more common in the 
treatment than placebo group, and this adverse effect was also seen in triptan monotherapy, so it was not believed to be caused by 
the interaction between the combined medication.  
The therapeutic maneuver highlighted in the manuscript is feasible in practice, especially in Ms. Brown. The authors instructed 
patients to take the medication within 1 hour of migraine attack onset, while the pain was still mild. Unlike other studies that waited 
until the pain was more severe, this increased the functional capacity of the study medication and is easily applicable to a broad 
population.7,1 
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A major confounding factor for this study was the support from GlaxoSmithKline (GSK). Not only did members of the organization 
support the RCT, but they also had input into the study design, data interpretation, and even participated in critical review of the 
manuscript. While all of the data collected was presented in the manuscript, the strong participation from GSK presents an increased 
likelihood of bias as they had a vested interest in the results. 
Clinical Application 
Ms. Brown presented to our clinic with poor response to her sumatriptan monotherapy, having 6-8 migraines per 
month. Her migraines were impacting her life, so she hoped for an addition to her sumatriptan to more effectively 
treat her pain. Her optimism and internal motivation to improve gave us an opportunity to assess the efficacy of 
the medication over time using journaling techniques pared with multiple check-up visits.  
The manuscript has internal validity with the results indicating an improvement in migraine pain with the 
sumatriptan/naproxen combination pill. Even in the poor-responder population, the addition of a second abortive 
medication with a different mechanism was likely to have a positive effect pain control, so the results make sense.  
The external validity of the manuscript is equally positive, as Ms. Brown showed a near immediate benefit from 
the combined medication. She reported that although the frequency of her migraines did not improve, she was 
able to abort them using the medication and was not forced to remove herself from activities, which was her goal. 
It was communicated that this improvement may not be permanent, and she may need to alter her regimen in the 
future, but she indicated that improvement in the short term was what she was most hopeful for. 
New Knowledge Related to Clinical Decision Science 
Ms. Brown’s hesitation to completely stop sumatriptan monotherapy even though she reported it as incompletely effective 
represents a common trend in patient care. Patients are hesitant to start unfamiliar medications even though they are clinically 
recommended.  In understanding her concerns, we were able to both treat her migraines with a combination pill that was similar to 
what she was accustomed to taking while also keeping her comfortable with the medical decision making. Generally, this should be 
viewed as a case study in how patient care should be modeled – ensuring patient’s questions are answered with clinical reasoning 
backed by literature, while maintaining patient-centered decisions. 
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